Skip to main content

biovu Archives

New high-tech biobank safeguards critical specimens

Aug. 25, 2022—by Bill Snyder Vanderbilt University Medical Center has opened a state-of-the-art automated biobanking system that can store as many as 10 million biospecimens, including blood and body fluids, tissue, and genetic and protein material, at temperatures down to minus 80 degrees Celsius. The “BioStore” was purchased from its manufacturer, Massachusetts-based Azenta Life Sciences, with the...

Read more


Genotype-specific blood counts

Aug. 11, 2022—Vanderbilt researchers report genotype-specific reference ranges to improve interpretation of laboratory blood results in African Americans with a common gene variant that lowers white blood cell counts.

Read more


Study shows genotype leads to discontinued, decreased medication

Jun. 29, 2022—  by Jill Clendening Patients whose race is recorded as Black in their electronic health record (EHR) are more likely to have azathioprine, an immunosuppressant medication, discontinued or its dose reduced because their laboratory results show a low white blood cell count. This lab finding was not a factor of race, but instead was linked...

Read more


BMI genetics influence heart function

Jun. 16, 2022—Vanderbilt researchers have discovered that a genetic predisposition to elevated body mass index increases the risk of diastolic dysfunction — a cardiac condition that can lead to heart failure.

Read more


BioVU celebrates 15 years supporting personalized medicine

Jun. 8, 2022—BioVU is celebrating its 15th year and has enabled hundreds of studies and publications exploring the genetic underpinnings of a host of conditions including cancer, heart disease and diabetes. 

Read more


Genetics and blood pressure

May. 19, 2022—Including polygenic risk scores for blood pressure may improve predictive models to identify people at risk for treatment-resistant hypertension.

Read more


A clue to an adverse drug event in children

May. 19, 2022—Considering metabolic (CYP2D6) enzyme activity score and patient age may aid in determining an individual’s risk for an adverse event with administration of the anti-arrhythmic drug propafenone.

Read more


Gene variants and transplant drug dose

May. 9, 2022—Genotyping multiple enzymes that metabolize the immunosuppressive drug tacrolimus — common used for lung transplant recipients — is important for correct dosing of the drug, Vanderbilt researchers found.

Read more


Gene network linked to Type 2 diabetes

May. 5, 2022—Vanderbilt researchers used a novel analytical approach to identify a network of genes associated with Type 2 diabetes, including 31 genes that had not previously been associated with the disease.

Read more


Calculating risk for uterine fibroids

Apr. 26, 2022—Vanderbilt researchers have constructed a polygenic risk score for uterine fibroids that will be useful for exploring causes of these benign tumors and identifying novel drug targets and therapies.

Read more


Major grant renewal to provide five more years of support for VICTR

Apr. 6, 2022—Vanderbilt University Medical Center has competed successfully for a third renewal of its Clinical and Translational Science Award by the National Institutes of Health.

Read more


Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development

Jan. 10, 2022—Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more